The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 4, 2004, Pages 337-343

  Grizzle, William E ^a   Semmes, O John ^b   Basler, Joseph ^c   Izbicka, Elzbieta ^d   Feng, Ziding ^e   Kagan, Jacob ^f   Adam, Bao Ling ^g   Troyer, Dean ^c   Srivastava, Sudhir ^f   Thornquist, Mark ^e   Zhang, Zhen ^h   Thompson, Ian M ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d CTRC Institute for Drug Development   (United States)

^e USA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Biomarkers; Cancer detection; Prostate cancer; Proteomics; SELDI

Indexed keywords

IMMUNOGLOBULIN G; INSULIN; PROSTATE SPECIFIC ANTIGEN;

ALGORITHM; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONFERENCE PAPER; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HIGH RISK POPULATION; HUMAN; MASS SPECTROMETRY; MEDICAL RESEARCH; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY CONTROL; REPRODUCIBILITY; ROBOTICS; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

BIOPSY; HUMANS; LASERS; MALE; MASS SCREENING; MASS SPECTROMETRY; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 3343026530     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2004.04.008     Document Type: Conference Paper

References (26)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer Statistics, 2004. CA Cancer J Clin. 54:2004;8-29
2. Middleton R.G., Thompson I.M., Austenfeld M.S., et al. The American Urological Association. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. J Urol. 154:1995;2144-2148
3. Gohagan J.K., Prorok P.C., Kramer B.S., Cornett J.E. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol. 152:1994;1905-1909
4. Wilt T.J., Brawer M.K. The Prostate Intervention Versus Observation Trial (PIVOT). Oncology. 11:1997;1133-1139
5. Ablin R.J. Prostate-specific antigen chronology of its identification. Oncology. 12:1998;1016
6. Thompson I.M., Ernst J.J., Gangai M.P., Spence C.R. Adenocarcinoma of the prostate results of routine urological screening. J Urol. 132:1984;690-692
7. Smith D.S., Catalona W.J. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol. 152:1994;1732-1736
8. DeAntoni E.P., Crawford E.D., Oesterling J.E., et al. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology. 48:1996;234-239
9. Roehl K.A., Antenor J.A., Catalona W.J. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/ml range. J Urol. 168:2002;922-925
10. Richardson T.D., Oesterling J.E. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am. 24:1997;339-351
11. Partin A.W., Brawer M.K., Bartsch G., et al. Complexed prostate specific antigen improves specificity for prostate cancer detection results of a prospective multicenter clinical trial. J Urol. 170:2003;1787-1791
12. Thompson I.M., Goodman P., Tangen C., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 349:2003;215-224
13. Zhukov T.A., Johanson R.A., Cantor A.B., Clark R.A., Tockman M.S. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer. 40:2003;267-279
14. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 48:2002;1296-1304
15. Adam B.L., Qu Y., Davis J.W., et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62:2002;3609-3614
16. Cazares L.H., Adam B.L., Ward M.D., et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res. 8:2002;2541-2552
17. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577
18. Petricoin E.F. III, Ornstein D.K., Paweletz C.P., et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 94:2002;1576-1578
19. Vlahou A., Schellhammer P.F., Mendrinos S., et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol. 158:2001;1491-1502
20. Adam B-L., Qu Y., Davis J.W., et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62:2002;3609-3614
21. Qu Y., Adam B.L., Yasui Y., et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem. 48:2002;1835-1843
22. Petricoin E.F., Ornstein D.K., Paweletz C.P., et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 94:2002;1576-1578
23. Pepe M.S., Etzioni R., Feng Z., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 93:2001;1054-1061
24. Thompson I.M., Goodman P.J., Tangen C.M., et al. The Influence of Finasteride on the Development of Prostate Cancer. N Engl J Med. 349:2003;213-222
25. Whitmore W.F., Warner J.A., Thompson I.M. Expectant management of localized prostate cancer. Cancer. 67:1991;1091-1096
26. Albertsen P.C., Hanley J.A., Gleason D.F., Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 280:1998;975-980